Budigalimab
- Generic Name
- Budigalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2098225-93-3
- Unique Ingredient Identifier
- 6VDO4TY3OO
- Background
Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT04799353
- Locations
- 🇺🇸
Central Texas Clinical Research /ID# 223937, Austin, Texas, United States
🇺🇸Franco Felizarta, Md /Id# 223931, Bakersfield, California, United States
🇺🇸Ruane Clinical Research Group /ID# 224496, Los Angeles, California, United States
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 362
- Registration Number
- NCT03821935
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia /ID# 221107, Valencia, Spain
🇺🇸University of Washington Medical Center /ID# 268854, Seattle, Washington, United States
🇺🇸Highlands Oncology Group, PA /ID# 218942, Springdale, Arkansas, United States
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT03639194
- Locations
- 🇺🇸
UH Cleveland Medical Center /ID# 207561, Cleveland, Ohio, United States
🇺🇸The Ohio State University /ID# 207552, Columbus, Ohio, United States
🇺🇸Highlands Oncology Group, PA /ID# 207176, Springdale, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.